<DOC>
	<DOCNO>NCT00003776</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug combine chemotherapy surgery may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy surgery treat patient newly diagnose metastatic osteosarcoma .</brief_summary>
	<brief_title>Combination Chemotherapy Surgery Treating Patients With Newly Diagnosed Metastatic Osteosarcoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy oral trimetrexate glucuronate simultaneous leucovorin calcium protection patient newly diagnose metastatic osteogenic sarcoma . II . Evaluate toxicity regimen administer prior follow standard chemotherapy patient osteogenic sarcoma . III . Correlate response vitro determinant chemotherapy resistance tumor sample obtain patient . OUTLINE : Patients receive induction therapy oral trimetrexate glucuronate ( TMTX ) leucovorin calcium every 12 hour 21 day ( week 0-2 ) . Patients receive leucovorin calcium 3 additional day last dose TMTX . If age prevents compliance oral administration , patient receive TMTX IV leucovorin calcium IV . Patients undergo definitive surgery 7-10 day induction therapy ( week 4 ) . Patients undergo surgery metastatic disease , indicate , soon possible follow recovery definitive surgery . Patients receive maintenance therapy every 3 week 8-9 month accord follow schedule : Patients receive ifosfamide IV 1 hour 4 time daily day 1-4 plus doxorubicin IV 48 hour day 1-2 week 6 , 14 , 22 , ifosfamide alone week 30 . Patients receive cisplatin IV 4 hour 1 day , plus doxorubicin IV 48 hour 2 day begin day first dose cisplatin , week 10 , 18 , 26 . Patients receive cisplatin alone week 34 . Patients receive filgrastim subcutaneously daily 2 week start 24 hour completion course ifosfamide cisplatin therapy . Patients receive methotrexate IV 4 hour 1 day , plus oral leucovorin calcium every 6 hour least 10 dos begin 20 hour last dose methotrexate , week 9 , 13 , 17 , 21 , 25 , 29 , 33 , 37 . In severe case , patient receive leucovorin calcium IV 24 hour . Patients respond induction therapy receive second course therapy week 38-40 . Patients follow every 4 month 1 year , every 6 month 2 year . PROJECTED ACCRUAL : A total 18-33 patient accrue study 2-3 year .</detailed_description>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Trimetrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm , newly diagnose ( within one month biopsy ) malignant high grade osteosarcoma Must pulmonary metastasis ( two nodule ) and/or disease involve bone organ Must intent resect least one primary and/or metastatic site follow preoperative chemotherapy Must least 1 evaluable site disease No radiation induce sarcoma No osteosarcoma arise premalignant bony lesion ( e.g . Paget 's disease ) PATIENT CHARACTERISTICS : Age : 30 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin le 3.0 time normal SGOT and/or SGPT le 3.0 time normal Renal : Creatinine great 1.5 time normal OR Creatinine clearance radioisotope GFR great 70 mL/min Cardiovascular : Shortening fraction great 28 % echocardiogram OR Ejection fraction great 50 % radionuclide angiogram No history pericarditis myocarditis PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunomodulating agent except steroid Chemotherapy : No prior chemotherapy No concurrent chemotherapy Endocrine therapy : No concurrent immunomodulating agent except steroid Radiotherapy : No prior concurrent radiotherapy Surgery : Prior biopsy primary metastatic area No prior resection Other : No prior therapy malignancy No concurrent cotrimoxazole</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>metastatic osteosarcoma</keyword>
</DOC>